You are here

  • Home
  • Archive
  • Volume 1, Issue 1
  • Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts

Article Text

Article menu

Download PDFPDF

Epidemiology
Extended report
Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts
  1. Ana Maria Gherghe1,2,
  2. Maxime Dougados3,
  3. Bernard Combe4,
  4. Robert Landewé5,
  5. Carina Mihai2,
  6. Francis Berenbaum6,7,
  7. Xavier Mariette8,
  8. Ron Wolterbeek9 and
  9. Désirée van der Heijde1
  1. 1Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
  2. 2Department of Internal Medicine and Rheumatology, Cantacuzino Clinical Hospital, Bucharest, Romania
  3. 3Department of Rheumatology, Paris Descartes University—Hôpital Cochin, Assistance Publique—hôpitaux de Paris—INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France
  4. 4Department of Rheumatology, Lapeyronie Hospital, Montpellier 1 University, Montpellier, France
  5. 5Clinical Immunology and Rheumatology Department, Academic Research Center/University of Amsterdam, Atrium Medical Center Heerlen, Heerlen, The Netherlands
  6. 6University Pierre et Marie Curie Paris VI, 7 quai Saint Bernard, Paris, France
  7. 7Department of Rheumatology, 2 AP-HP Saint-Antoine hospital, and Department Hospitalo-Universitaire Inflammation-Immunopathology-Biotherapy (I2B), Paris, France
  8. 8Department of Rheumatology, Hôpitaux Universitaires Paris Sud, Université Paris Sud, AP-HP, INSERM U1012, Le Kremlin-Bicêtre, France
  9. 9Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands
  1. Correspondence to Ana Maria Gherghe; ana.gherghe{at}gmail.com

Abstract

Objectives To investigate the prevalence of comorbidities in early rheumatoid arthritis (ERA) and early axial spondyloarthritis (ESpA) versus the general population.

Methods Baseline data of 689 patients with ERA from the Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) cohort (age 48.2±12.1 years, symptoms duration 14.2±14.5 weeks) and 645 patients with ESpA from Devenir des Spondylarthropathies Indifférenciées Récentes (DESIR; age 32.8±8.4 years, axial symptoms duration 79.0±45.7 weeks) were analysed. Metabolic and cardiovascular diseases (CVD), infections and neoplasia were determined in each cohort. The prevalence (95% CI) of several comorbidities was compared with that in the French general population. For patients without CVD, the 10-year risk of developing CVD was calculated using the Framingham and SCORE equations. The heart age was calculated using the 2008 Framingham points system.

Results 42% of patients with ERA and 20.3% of patients with ESpA had at least 1 comorbidity; the most common were arterial hypertension (AHT) and dyslipidaemia. AHT prevalence (95% CI) in ERA (18.2% (15.5% to 21.3%)), but not in ESpA (5.08% (3.57% to 7.14%)), was significantly increased (p<0.05) compared with the general population (7.58%). Prevalence of tuberculosis history was higher in ERA (4.7% (3.3% to 6.6%)), and ESpA (0.99% (0.4% to 2.3%)) than in the general population (0.02%; both p<0.05). No differences were observed in malignancies, coronary heart disease or diabetes. In ERA, among patients without a history of CVD, an intermediate to high CVD risk was found. The heart age exceeded the real age by 4.1±9.6 years in ERA and by 2.1±7.0 years in ESpA (p<0.001).

Conclusions We found an increased prevalence of AHT and tuberculosis history in ERA and ESpA, and an increased CVD risk. These results should prompt rheumatologists to check these comorbidities early in the disease.

  • Rheumatoid Factor
  • Spondyloarthritis
  • Cardiovascular Disease
  • Tuberculosis

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/rmdopen-2015-000128

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Supplementary materials

    • Supplementary Data

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.